Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
Talquetamab Utilization Patterns and Dose Schedules in the United States: A Real-World Analysis
Rahul Banerjee, MD
Assistant Professor, Clinical Research Division
Fred Hutchinson Cancer Center
Seattle, Washington, United States